Network News

X My Profile
View More Activity
Column Archive |  On Twitter: J Huget and MisFits  |  Fitness & Nutrition News  |  RSS Feeds RSS Feed

FDA approves first oral drug to modify MS course

The U.S. Food and Drug Administration on Wednesday approved the first oral disease-modifying drug for multiple sclerosis, making an appealing new treatment option available to hundreds of thousands of people with a common form of the disease.

Fingolimod capsules, to be marketed as Gilenya by drug-maker Novartis International AG, have been shown to reduce the incidence of MS symptoms and slow development of physical disability among people with relapsing MS. Novartis says the drug will be available for prescription in coming weeks.

The capsule may prove a boon to people who shy away from needles; existing MS disease-modifying therapies are administered by injection or intravenously. It's unclear yet how much the drug will cost and what the insurance coverage scene will be. But people can be prescribed Gilenya without having to try other treatments first. Compliance with treatment plans is a big issue in MS; many people don't believe the benefits of existing drugs outweigh the hassle of the injections.

Still, it's unclear how many people currently using injectable MS treatments will switch to the new oral drug. Patients are advised to talk with their doctors about that. For many, the potential and serious side effects -- including increased risk of infection and toxicity to the eyes, liver, lungs and heart -- may encourage continuing with their needle-injected drugs, most of which are free of serious side effects.

Me? I'm planning to stick with my daily shot, which seems to have served me well for the nine-plus years I've been on it. I'm so used to the bruises and funky indentations in my skin that come after years of poking myself, I'm in no hurry to change. But I'm really happy for the people who might seek treatment, now that no needle's needed. And I'm really happy to see the fight against MS continue. Maybe one day soon there'll be a cure.

By Jennifer LaRue Huget  | September 23, 2010; 7:00 AM ET
Categories:  Multiple Sclerosis, Neurological disorders  
Save & Share:  Send E-mail   Facebook   Twitter   Digg   Yahoo Buzz   Del.icio.us   StumbleUpon   Technorati   Google Buzz   Previous: Bill Clinton, burger-free?
Next: New study questions mammograms

No comments have been posted to this entry.

Post a Comment

We encourage users to analyze, comment on and even challenge washingtonpost.com's articles, blogs, reviews and multimedia features.

User reviews and comments that include profanity or personal attacks or other inappropriate comments or material will be removed from the site. Additionally, entries that are unsigned or contain "signatures" by someone other than the actual author will be removed. Finally, we will take steps to block users who violate any of our posting standards, terms of use or privacy policies or any other policies governing this site. Please review the full rules governing commentaries and discussions.




characters remaining

 
 
RSS Feed
Subscribe to The Post

© 2010 The Washington Post Company